title: Early and late mortality in patients undergoing transcatheter aortic valve implantation: comparison of the novel EuroScore II with established risk scores.
abstract: OBJECTIVE
  In the evaluation of patients considered for transcatheter aortic valve implantation (TAVI), the EuroScore II might be superior to established risk scores.
  
  
  METHODS
  We assessed the performance of the EuroScore II in predicting mortality in a cohort of 350 TAVI patients.
  
  
  RESULTS
  The EuroScore II and the logistic EuroScore were higher in nonsurvivors compared to survivors at 30 days (12.6 ± 1.8 vs. 7.5 ± 0.3%, p < 0.001 for EuroScore II, and 27.7 ± 2.8 vs. 22.1 ± 0.8%, p = 0.04 for logistic EuroScore), while the STS-PROM score did not differ (7.3 ± 0.8 vs. 6.4 ± 0.3%, p = 0.09). The area under the curve (AUC) was 0.70 for the EuroScore II, 0.61 for the logistic EuroScore and 0.59 for the STS-PROM score for predicting 30-day mortality. Based on the estimated 30-day mortality risk, 3 risk groups were identified, a low-risk (EuroScore II ≤4%, 30-day mortality 1.2%), an intermediate-risk (EuroScore II between 4% and 9%, 30-day mortality 8.6%) and a high-risk group (EuroScore II >9%, 30-day mortality, 17.1%; p = 0.03). Regarding cumulative mortality, the AUC was 0.67 for the EuroScore II, 0.62 for the logistic EuroScore and 0.55 for the STS-PROM score for predicting mortality at total follow-up.
  
  
  CONCLUSIONS
  In this patient cohort, the EuroScore II performed best in predicting short- and long-term mortality.
authors.affiliation: Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland.
authors.forename: Barbara E
authors.initials: BE
authors.lastname: Stähli
authors.forename: Hanna
authors.initials: H
authors.lastname: Tasnady
authors.forename: Thomas F
authors.initials: TF
authors.lastname: Lüscher
authors.forename: Cathérine
authors.initials: C
authors.lastname: Gebhard
authors.forename: Fran
authors.initials: F
authors.lastname: Mikulicic
authors.forename: Ladina
authors.initials: L
authors.lastname: Erhart
authors.forename: Ines
authors.initials: I
authors.lastname: Bühler
authors.forename: Ulf
authors.initials: U
authors.lastname: Landmesser
authors.forename: Lukas
authors.initials: L
authors.lastname: Altwegg
authors.forename: Manfred B
authors.initials: MB
authors.lastname: Wischnewsky
authors.forename: Jürg
authors.initials: J
authors.lastname: Grünenfelder
authors.forename: Volkmar
authors.initials: V
authors.lastname: Falk
authors.forename: Roberto
authors.initials: R
authors.lastname: Corti
authors.forename: Willibald
authors.initials: W
authors.lastname: Maier
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001021:Aortic Valve / Q000601:surgery*; D001024:Aortic Valve Stenosis / Q000401:mortality / Q000601:surgery*; D005260:Female; D006350:Heart Valve Prosthesis / Q000706:statistics & numerical data*; D019918:Heart Valve Prosthesis Implantation / Q000379:methods / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012372:ROC Curve; D018570:Risk Assessment / Q000379:methods